Ipsen Investor Relations Material
Latest events
Q1 2024 TU
Ipsen
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Ipsen S.A.
Access all reports
Ipsen S.A. provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders and rare diseases. The company's products include Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell ad second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure and GH deficiency in adults; Increlex for growth failure in children and adolescents.
Key slides for Ipsen S.A.
Q3 2023 TU
Ipsen S.A.
Q1 2024 TU
Ipsen S.A.
Latest articles
Bill Gates: The Man Who Put a Computer in Every Home
Explore the life of Bill Gates, from co-founding Microsoft to global philanthropy, and his lasting impact on the world.
2 May 2024
The Lego Story: Building a Business Brick by Brick
A detailed account of the most important milestones in the Lego Group's history, as well as an explanation of the philosophy guiding the company
2 May 2024
Kevin Plank and the Rise of Under Armour
Dive into the story of Under Armour and its founder Kevin Plank, highlighting both successes and mistakes.
30 Apr 2024
Ticker symbol
Country
🇫🇷 France